ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "osteoporosis"

  • Abstract Number: 111 • 2014 ACR/ARHP Annual Meeting

    Low Rates of Bone Mineral Density Testing in Medicare Beneficiaries with Breast Cancer Starting Aromatase Inhibitor Therapy

    Mamatha Siricilla1, Ruili Luo2, Linda Elting2 and Maria E. Suarez-Almazor1, 1The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, 2The Department of Health Services Research, The University of Texas, MD Anderson Cancer Center, Houston, TX

    Background/Purpose Aromatase inhibitors (AI) are increasingly used as adjuvant hormonal therapy in postmenopausal women with estrogen receptor-positive breast cancer. It is well recognized that therapy…
  • Abstract Number: 50 • 2014 ACR/ARHP Annual Meeting

    Incidence and Risk Factors for Osteoporotic Vertebral Fracture in Low-Income Community-Dwelling Elderly: A Population-Based Prospective Cohort Study in Brazil. the São Paulo Ageing & Health (SPAH) Study

    Diogo S. Domiciano1, Luana G. Machado2, Jaqueline B. Lopes2, Valéria Caparbo2, Liliam Takayama2, Ricardo M. Oliveira3 and Rosa M. R. Pereira4, 1Rheumatology, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil, 2Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 3RDO Diagnosticos Medicos, São Paulo, Brazil, 4Reumatologia, Faculdade de Medicina, University of São Paulo, São Paulo, Brazil

    Background/Purpose: Vertebral fractures are associated with increased future fracture risk and mortality. No data on incidence of osteoporotic vertebral fracture have been reported in low-income…
  • Abstract Number: 2314 • 2014 ACR/ARHP Annual Meeting

    Dexa Testing in Long-Term Steroid Use

    Beth Scholz, Internal medicine, University of Texas Health Science Center at Houston, Houston, TX

    Background/Purpose: Risk stratification in the ACR glucocorticoid-induced osteoporosis guidelines includes DEXA testing, which is not universally implemented at our rheumatology clinic. DEXA utilization should be…
  • Abstract Number: 2732 • 2013 ACR/ARHP Annual Meeting

    Inhibition Of Autophagy Prevents Ovariectomy Induced Bone Loss

    Neng-Yu Lin1, Joerg H. W. Distler1, Alfiya Distler1, Christian Beyer1, Georg Schett2 and Oliver Distler3, 1Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 2Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, 3Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland

    Background/Purpose: Autophagy is an essential, homeostatic process by which cells digest unnecessary or damaged organelles. Atg7 is essentially required for formation of the autophagosome. The…
  • Abstract Number: 2664 • 2013 ACR/ARHP Annual Meeting

    Evaluation Of Osteoporosis Medication Starts In Patients Based On T-Score and FRAX® Absolute Fracture Risk Model In a Large Health Care System

    Robert A. Overman1,2 and Chad L. Deal3, 1Eshelman School of Pharmacy - Division of Pharmaceutical Policy and Outcomes, University of North Carolina, Chapel Hill, NC, 2Rheumatology, Cleveland Clinic, Cleveland, OH, 3Dept of Rheum & Imm Dis /A 50, Cleveland Clinic, Cleveland, OH

    Background/Purpose: The National Osteoporosis Foundation (NOF) 2008 guidelines recommend treatment for postmenopausal women (PMW) and men ≥ 50 if the T-score is ≤-2.5 at the…
  • Abstract Number: 2266 • 2013 ACR/ARHP Annual Meeting

    Research On Factors Influenced For Bone Metabolic Markers In Rheumatoid Arthritis Patients From Prospective Cohort Study

    Masahiro Tada1, Tatsuya Koike2, Tadashi Okano1, Yuko Sugioka1, Kenji Mamoto1, Kentaro Inui3 and Hiroaki Nakamura1, 1Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, 2Rheumatosurgery, Osaka City University Graduate School of Medicine, Osaka, Japan, 3Orhtopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan

    Background/Purpose: Patients with rheumatoid arthritis (RA) develop osteoporosis more frequently than healthy individuals. Bone resorption and formation are respectively increased and inhibited in patients with…
  • Abstract Number: 2213 • 2013 ACR/ARHP Annual Meeting

    Anti-IL-6 Receptor Antibody Normalizes Both DKK-1 and Sclerostin As Wnt Inhibitors In a Mouse Model Of Collagen-Induced Arthritis

    Hiroto Yoshida1, Mika Yagoto1, Miho Suzuki1, Keisuke Tanaka1, Isao Matsumoto2, Takayuki Sumida3 and Yoshihiro Matsumoto1, 1Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, 2Department of Internal Medicine, Faculty of Medicine,, University of Tsukuba, Tsukuba, Japan, 3Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan

    Background/Purpose: The Wnt pathway plays an important role in bone formation and regeneration. This pathway is regulated by several soluble inhibitors such as Dickkopf-1 (DKK-1)…
  • Abstract Number: 1924 • 2013 ACR/ARHP Annual Meeting

    Cleveland Clinic Dual Energy X-Ray Absorptiometry Registry, A Web-Based Tool Designed For Efficient Collection Of Bone Density and Osteoporosis Related Clinical Risk Factor Data

    Chad L. Deal1, Gregory J. Strnad2, Robert A. Overman3,4 and Boris Bershadsky2,5, 1Dept of Rheum & Imm Dis /A 50, Cleveland Clinic, Cleveland, OH, 2Orthopaedic and Rheumatologic Institute, Cleveland Clinic, Cleveland, OH, 3Eshelman School of Pharmacy - Division of Pharmaceutical Policy and Outcomes, University of North Carolina, Chapel Hill, NC, 4Rheumatology, Cleveland Clinic, Cleveland, OH, 5School of Public Health, University of Minnesota, Minneapolis, MN

    Background/Purpose: A patient registry is an organized system that collects uniform data to allow evaluation of specific outcomes for a population with a particular disease.…
  • Abstract Number: 1785 • 2013 ACR/ARHP Annual Meeting

    Structural Determinants Of Low Vertebral Strength In Pediatric Systemic Lupus Erythematosus

    Jon M. Burnham1, Babette S. Zemel1, David C. Lee2, Tony M. Keaveny3 and Mary Beth Leonard1, 1Pediatrics, The Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, 2O.N. Diagnostics, LLC, Berkeley, CA, 3Founder and Chief Science Officer, University of California, Berkeley, CA and O.N. Diagnostics, LLC, Berkeley, CA

    Background/Purpose: Children with systemic lupus erythematosus (SLE) are at high risk for bone fragility.  Studies in pediatric SLE using two-dimensional lumbar spine (LS) dual X-ray…
  • Abstract Number: 1243 • 2013 ACR/ARHP Annual Meeting

    Osteoporosis Medication Adherence: Reasons For Stopping and Not Starting

    Amy H. Warriner1, Ryan C. Outman2, Allison Wyman3, Fred H. Hooven4, Jonathan D. Adachi5, Roland Chapurlat6, Juliet E. Compston7, Cyrus Cooper8, Jeffrey R. Curtis9, Adolfo Díez-Pérez10, Robert Lindsay11, Lyn March12, Jeri W. Nieves11 and Kenneth G. Saag13, 1Endocrinology, Diabetes, and Metabolism, The University of Alabama at Birmingham, Birmingham, AL, 2Preventive Medicine, University of Alabama at Birmingham, Birmingham, AL, 3Center for Outcomes Research, Center for Outcomes Research, UMass Medical School, Worcester, MA, 4University of Massachusetts, Worcester, MA, 5McMaster University, Hamilton, ON, Canada, 6Service de Rhumatologie et Pathologie Osseuse, INSERM UMR 1033 and Université de Lyon, Hôpital Edouard Herriot, Lyon, France, 7University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom, 8MRC Lifecourse Epidemiology Unit, Southampton, United Kingdom, 9Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 10Internal Medicine, Hospital del Mar-IMIM, Universitat Autònoma de Barcelona, Barcelona; and RETICEF, ISCIII Madrid; Spain, Barcelona, Spain, 11Helen Hayes, West Haverstraw, NY, 12Rheumatology, Institute of Bone and Joint Research, Kolling Institute, University of Sydney, Sydney, Australia, 13Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Medication adherence with prescription osteoporosis medications is poor, with approximately half remaining adherent in the first year of treatment. Moreover, approximately one-third who are…
  • Abstract Number: 1224 • 2013 ACR/ARHP Annual Meeting

    Prednisone Has No Effect On Odanacatib Pharmacokinetics In Healthy Subjects

    Gene Marcantonio1, Chengcheng Liu2, Stefan Zajic3, Chantal Mahon2, David Hreniuk2, Anish Mehta4, Kate Mostoller2, Denise Morris5, Hongwei Xue5 and S. Aubrey Stoch2, 1Merck & Co., Whitehouse Station, NJ, 2Merck Sharp & Dohme Corp., Whitehouse Station, NJ, 3Merck Sharp & Dohme Corp, Whitehouse Station, NJ, 4Merck Sharp & Dohme Corp.,, Whitehouse Station, NJ, 5Covance, Madison, WI

    Background/Purpose: We evaluated the effect of prednisone, a glucocorticoid believed to induce the CYP P450 enzyme, on the pharmacokinetics of odanacatib, a novel Cathepsin K…
  • Abstract Number: 1226 • 2013 ACR/ARHP Annual Meeting

    Adherence With Current Osteoporosis Treatment Guidelines Among Rheumatologists Caring For Patients With Rheumatoid Arthritis Using Items From The Fracture Risk Assessment Tool Score

    Jennifer Watt1, Andrew E. Thompson2, Nicole G. H. Le Riche3 and Janet E. Pope4, 1Medicine, University of Western Ontario, London, ON, Canada, 2Rheumatology, St. Josephs Health Ctr, London, ON, Canada, 3Department of Medicine, St. Joseph's Hospital, London, ON, Canada, 4Medicine, Divsion of Rheumatology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada

    Background/Purpose: To assess whether the Fracture Risk Assessment Tool (FRAX) score in patients with RA correlates with likelihood of osteoporosis (OP) prescription including drug treatment,…
  • Abstract Number: 982 • 2013 ACR/ARHP Annual Meeting

    Preferred Strategies For Delivering Treatment Information To People With Rheumatoid Arthritis, Osteoarthritis and Osteoporosis

    Maria A. Lopez-Olivo1, Robert Volk2, Maria Jibaja-Weiss3 and Maria E. Suarez-Almazor4, 1General Internal Medicine, University of Texas. M.D Anderson Cancer Center, Houston, TX, 2General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, 3Office of Outreach and Health Disparities, Baylor College of Medicine, Houston, TX, 4The Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX

    Background/Purpose: To explore the perceptions of people with rheumatoid arthritis (RA), osteoarthritis (OA), and osteoporosis (OP) regarding their preferred delivery methods for obtaining treatment information…
  • Abstract Number: 2079 • 2012 ACR/ARHP Annual Meeting

    Anti-Interleukin-6 Receptor Antibody Improves Systemic Osteoporosis in a Mice Model of Glucose-6-Phosphate Isomerase-Induced Arthritis

    Hiroto Yoshida1, Miho Suzuki1, Misato Hashizume1, Keisuke Tanaka2, Masashi Shiina2, Isao Matsumoto3, Takayuki Sumida3 and Yoshihiro Matsumoto2, 1Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, 2Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan, 3Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba City, Japan

    Background/Purpose: Patients with rheumatoid arthritis (RA) have a high risk of osteoporosis and osteoporotic fracture. In addition to the primary risk factors for osteoporosis, osteoporosis…
  • Abstract Number: 1991 • 2012 ACR/ARHP Annual Meeting

    Effects of Odanacatib On the Distal Radius and Tibia in Postmenopausal Women: Improvements in Cortical Geometry and Estimated Bone Strength

    Roland Chapurlat1, K. Brixen2, A.M. Cheung3, Sharmila Majumdar4, B. Dardzinski5, A. Cabal5, N. Verbruggen6, S. Ather5, Elizabeth Rosenberg5 and A. de Papp5, 1Hôpital Edouard Herriot, Lyon, France, 2University of Southern Denmark, Odense, Denmark, 3University of Toronto, Ontario, Canada, 4University of California San Francisco, San Francisco, CA, 5Merck Sharp & Dohme Corp., Whitehouse Station, NJ, 6MSD Belgium, Brussels, Belgium

    Background/Purpose: The cathepsin K inhibitor odanacatib (ODN), a novel antiresorptive that preserves bone formation, is currently in phase 3 development for postmenopausal osteoporosis.  In a…
  • « Previous Page
  • 1
  • …
  • 17
  • 18
  • 19
  • 20
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology